Leading life sciences organizations rely on AI to accelerate life-changing research and transform the future of drug discovery. Here, Mark Heuser, who leads the global partner ecosystem development for data center in healthcare and life sciences at NVIDIA, joins HPE's Rich Bird to see how HPE and NVIDIA are working together to deliver a robust AI platform to ramp up development and advance the science of medicine.
If your organization is involved in drug development, you donโt need us to tell you that itโs a lengthy and expensive process. Only one out of thousands of compounds makes it through the research, clinical trial, and regulatory review pipelines. Even fewer are approved and put into large-scale manufacturing. Analyzing new compounds is key to identifying promising new
Thatโs why many life sciences organizations are using artificial intelligence (AI) to accelerate in silico drug discovery. With legacy technologies running data analysis, the industry has seen a dramatic increase in research and development (R&D) costs. R&D spending is expected to continue to rise from $83 billion in 2019 to roughly $203.9 billion by 2024. Despite the excess spending, the industry is projected to see a decline in drug discovery with fewer new drugs brought to market.
Advances in AI can dramatically shorten drug discovery cycles
Combined with accelerated computing technologies, AI can rapidly consume huge amounts of life sciences data and break through computational bottlenecks to gain faster insights. The ability to capture, share, and predict R&D outcomes speeds up the drug discovery pipelineโfrom investigation and assessment to creation of tailored drugs and therapies.
Today, life sciences organizations are adopting innovative AI tools to meet the increasing demand for drug processing and analysis. Computational chemistry enhances the entire drug discovery chain, enabling greater intelligence and higher productivity to understand disease biology, accurately make predictions, and increase the speed with which clinical trials can be started. Many researchers are using cutting-edge analytics instruments like cryo-EM with computational methods to unlock even more value from data:
- Scaling up to handle large workloads
- Making life sciences data accessible from anywhere, at any time
- Accelerating the development of new therapies for complex diseases
- Shortening time from drug discovery to delivery to patients
These cutting-edge technologies make it possible to produce better drugs in less time for a wider range of debilitating diseases.
HPE and NVIDIA have partnered to bring computational drug discovery tools to customers faster. We offer industry-leading solutions and best practices to enable extreme agility and performance at any scale. With high sensitivity and precision for drug discovery, organizations can achieve results that are 99.9% accurate.
Our AI platform combines the latest in compute, storage, interconnects, software, and services to create a robust end-to-end solution. Built on HPE systems that are NVIDIA-certified, the platform is optimized for NVIDIA Clara Discovery for computational drug development tools and NVIDIA Clara Parabricks. Organizations can adopt these solutions on-premises, hybrid, or by paying for only what they use through HPE GreenLake to help simplify platform management, reduce costs and complexity, and scale AI on demand.
To optimize workflows for AI model development, deployment, and maintenance for accelerated workflows in healthcare, life sciences and drug discovery, customers can leverage the NVIDIA AI Enterprise software suite, which runs on NVIDIA-Certified Systems from HPE. An end-to-end, cloud-native suite of AI and data science tools, NVIDIA AI Enterprise runs on VMware vSphere and includes key enabling technologies and software from NVIDIA for rapid deployment, management, and scaling of AI workloads in the modern hybrid cloud on virtual machines and with Kubernetes containers.
HPE Pointnext services offer a broad spectrum of professional, technical, and advisory support for drug discoveryโwith services like application tuning, project management, on-site consulting, and solution architecture consulting. Our services make it easy to build your ideal life sciences solutions, so you can focus on accelerating research.
The new age of drug research innovation
AI delivers excellent performance and precision to revolutionize drug discovery. The latest solutions will fuel data analysis to bring life-saving drugs and therapeutics to market faster.
As more organizations implement and scale AI solutions to enhance their research, they will need trusted partners to help them boost productivity at each stage of the drug discovery cycle. HPE and NVIDIA are leaders in life sciences innovation, applying our extensive AI expertise to power some of the most demanding research environments. Whatever the workload requirements, our AI platform gives organizations the right tools to achieve more value from life sciences data. Organizations have already seen tremendous results, such as screening two billion compounds 33x faster and screening 10 million drugs 100x faster. Now, workloads that once took weeks take days, and workloads that took hours take minutes.
The world needs better drugs, vaccines, and therapeutics. Let us help you transform your drug discovery process to power the next scientific breakthrough. Together, HPE and NVIDIA can help you pioneer a new age of genomics research. Let us help you see how AI solutions can accelerate the next generation of drug discovery.
Join us at GTC
HPE is a Diamond sponsor at NVIDIA GTC, March 21-24. Register today to hear the latest news and learn how breakthrough AI discoveries can solve the world's biggest challenges while transforming your business.
Meet our Tech Insights guest blogger, Mark Heuser, NVIDIA
Insights Experts
Hewlett Packard Enterprise
twitter.com/HPE_AI
linkedin.com/showcase/hpe-ai/
hpe.com/us/en/solutions/artificial-intelligence.html
Rich_Bird
Rich Bird has worked in the IT industry for 20 years with some of the largest commercial brands. For the last 5 years heโs been focused on healthcare IT at Hewlett Packard Enterprise, and believes deeply that digital technologies can, will and need to have an impact on the delivery of better healthcare, for people all over the world. Educated in Computer Science at Coventry University, and starting his career as a network engineer for Rolls Royce, he moved into human communications roles in 2006. Rich leads teams in delivering integrated marketing campaigns into National, local and regional Governments in the UK, where Rich found his passion for making the complex concepts of IT, simple and understandable for his audience. During this time he found his true calling, Healthcare, and how digitization can improve real people lives. He created a companywide growth board focusing on the UK NHS, pulling together disparate teams of sales, marketing, solutions architects, chief technologists and the country leadership teams for HP/HPE UK. Rich is a strategic thinker who understands the practical elements that are required to get the job done and deliver real impact. His areas of specialization include Healthcare IT, Marketing, Communications, and NLP.